請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9770完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Feng-Yu Sung | en |
| dc.contributor.author | 宋豐伃 | zh_TW |
| dc.date.accessioned | 2021-05-20T20:40:19Z | - |
| dc.date.available | 2018-12-31 | |
| dc.date.available | 2021-05-20T20:40:19Z | - |
| dc.date.copyright | 2008-09-11 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-24 | |
| dc.identifier.citation | 1.Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946-52.
2.Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9. 3.Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74. 4.Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72. 5.Yuen MF, Tanaka Y, Shinkai N, Poon RT, But D, Fong DYT, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. British Medical Journal 2008;57:98. 6.Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004;127:1733-8. 7.Yuen MF, Fung SK, Tanaka Y, Kato T, Mizokami M, Yuen JCH, et al. Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. Journal of Clinical Microbiology 2004;42:5036. 8.Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48 Suppl 1:S2-19. 9.Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. 10.Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81. 11.Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. In: Am Med Assoc; 2006. p. 65-73. 12.Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. In: Oxford Univ Press; 2008. p. 106. 13.Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol 2004;14:3-16. 14.Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-107. 15.Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005;12:456-64. 16.Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005;43:411-7. 17.Sakugawa H, Nakasone H, Nakayoshi T, Orito E, Mizokami M, Yamashiro T, et al. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 2002;67:484-9. 18.Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218-23. 19.Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327-34. 20.Chen CH, Lee CM, Lu SN, Changchien CS, Eng HL, Huang CM, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005;43:6000-6. 21.Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007;27:1356-63. 22.Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57:91-7. 23.Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-9. 24.Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193:1258-65. 25.Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994;19:1366-70. 26.Karino Y, Toyota J, Sato T, Ohmura T, Yamazaki K, Suga T, et al. Early Mutation of Precore (A1896) Region Prior to Core Promoter Region Mutation Leads to Decrease of HBV Replication and Remission of Hepatic Inflammation. Digestive Diseases and Sciences 2000;45:2207-2213. 27.Chen WN, Oon CJ. Mutations and deletions in core promoter and precore stop codon in relation to viral replication and liver damage in Singaporean hepatitis B virus carriers. Eur J Clin Invest 2000;30:787-92. 28.Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. 29.Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-73. 30.Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15. 31.Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-12. 32.Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006;130:1153-68. 33.Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1098-103. 34.Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007;133:1466-74. 35.Kalinina T, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003;38:1274-81. 36.Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003;23:5-20. 37.Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23. 38.Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-7. 39.Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-44. 40.Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24 Suppl 1:3-10. 41.Lee YI, Hur GM, Suh DJ, Kim SH. Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: naturally occurring escape mutants. Journal of General Virology 1996;77:1129-1138. 42.Bertoletti A, Southwood S, Chesnut R, Sette A, Falco M, Ferrara GB, et al. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology 1997;26:1027-34. 43.Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993;177:751-62. 44.Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88:214-22. 45.Cao T, Desombere I, Vanlandschoot P, Sallberg M, Leroux-Roels G. Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. J Gen Virol 2002;83:3023-33. 46.Sallberg M, Ruden U, Magnius LO, Harthus HP, Noah M, Wahren B. Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol 1991;33:248-52. 47.Colucci G, Beazer Y, Cantaluppi C, Tackney C. Identification of a major hepatitis B core antigen (HBcAg) determinant by using synthetic peptides and monoclonal antibodies. J Immunol 1988;141:4376-80. 48.Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, et al. Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. J Med Virol 2004;72:370-6. 49.Liu Z, Luo K, He H, Hou J. Hot-spot mutations in hepatitis B virus core gene: eliciting or evading immune clearance? J Viral Hepat 2005;12:146-53. 50.Lee SM, Park SG, Park E, Lee JY, Jung G. The 113th and 117th charged amino acids in the 5th alpha-helix of the HBV core protein are necessary for pgRNA encapsidation. Virus Genes 2003;27:227-35. 51.Koschel M, Oed D, Gerelsaikhan T, Thomssen R, Bruss V. Hepatitis B virus core gene mutations which block nucleocapsid envelopment. J Virol 2000;74:1-7. 52.Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology 2007;365:285-91. 53.Ehata T, Omata M, Chuang WL, Yokosuka O, Ito Y, Hosoda K, et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993;91:1206-13. 54.Akarca US, Lok AS. Naturally occurring hepatitis B virus core gene mutations. Hepatology 1995;22:50-60. 55.Luo KX, Yang J, Liang ZS. [Correlation between HBV pre-C/C gene mutations and advanced pathologic activity in chronic hepatitis B]. Zhonghua Nei Ke Za Zhi 1994;33:763-6. 56.Ni YH, Chang MH, Hsu HY, Tsuei DJ. Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut 2003;52:122-5. 57.Kim HJ, Lee DH, Gwak GY, Choi MS, Lee JH, Koh KC, et al. Analysis of the core gene of hepatitis B virus in Korean patients. Liver Int 2007;27:633-8. 58.鍾君明. B型肝炎病毒核基因序列變異與肝細胞癌之關係：重疊病例對照研究 台灣大學; 2006. 59.Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. Journal of General Virology 2006;87:1439-1449. 60.Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell 2006;3:97-106. 61.Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008;48:335-352. 62.Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45. 63.Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. 64.Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52. 65.Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, et al. Viral Quasi-Species Evolution During Hepatitis Be Antigen Seroconversion. Gastroenterology 2007;133:951-958. 66.Koschel M, Thomssen R, Bruss V. Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation. J. Virol 1999;73:2153–2160. 67.Nassal M. The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J Virol 1992;66:4107. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9770 | - |
| dc.description.abstract | 背景：HBV core 基因所產生的HBcAg，是毒殺性T淋巴球主要的攻擊目標，core基因突變會使得被免疫系統辨識的抗原決定位發生改變，因而逃脫免疫反應。本研究探討HBV core基因上的突變和肝細胞癌(hepatocellular carcinoma；HCC)自然史的關係。
材料與方法：第一階段先利用nested case-control study所獲得定序分析資料找尋和HCC顯著相關之genotype-independent 單點核苷酸變異(single nucleotide polymorphisms；SNP)；第二階段對所找到的SNPs，發展適當的TaqMan probe，在一個追蹤16年的case-cohort study偵測SNPs在長時間的穩定性，及SNPs對病毒因子和疾病狀態的影響。 結果：經過整個core基因的全區域掃描，我們發現五個genotype-independent SNPs對於HCC有保護作用。在基線時，帶有這些SNPs之變異型者，其HBV DNA濃度、HBeAg陽性率皆顯著低於野生型，anti-HBe則相反，而且所帶有的變異型數目和HCC或HBeAg陽性狀態呈直線負相關。在追蹤期間，變異型相對於野生型穩定性較低。具有變異型者其追蹤期間ALT異常和肝硬化的比率皆顯著低於野生型，同時這些變異型和HBV DNA長期變動趨勢具有緊密相關性。 結論：HBV core基因突變和HBeAg陰轉及病毒複製活性有關，並有可能影響後續疾病狀態。 | zh_TW |
| dc.description.abstract | Background & Aims: HBcAg which is encoded by HBV core gene is immunological target of cytotoxic T cell. Genetic variation in the core gene changes the structure of epitope and escapes immune response. We investigated the association between genetic variation in the HBV core gene and natural history of hepatocellular carcinoma (HCC).
Materials & Methods: First, we used sequence data from a nested case-control study to identify genotype-independent single nucleotide polymorphisms (SNPs) associated with HCC. At the second stage, we developed novel TaqMan probes for identification of viral SNPs. Then an investigation was performed with a case-cohort study on the longitudinal stability of SNPs and their effects on the change of viral factors and disease progression over 16 years of follow-up. Results: We found five genotype-independent SNPs inversely associated with the risk of HCC through a scan of the whole core gene region. At baseline, harboring mutants of the above SNPs were associated with a lower plasma HBV DNA levels and HBeAg-positive rate but a higher prevalence of anti-HBe positivity. There was an inverse linear relationship for the accumulation of core gene mutants with HCC risk and HBeAg positivity. During follow-up, mutants exhibited a lower stability than wild type. The emergence of mutants was associated with sustained normalization of ALT and decreased risk of cirrhosis. It was tightly correlated with change in HBV DNA over time. Conclusions: Mutation in the HBV core gene may play some role in the HBeAg seroconversion and HBV replication activity, and thus affect disease progression. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-20T20:40:19Z (GMT). No. of bitstreams: 1 ntu-97-R95842004-1.pdf: 332797 bytes, checksum: 6e73051b136d91e67df37bb8e13bb369 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 致謝……………………………………………………………………i
中文摘要………………………………………………………………ii 英文摘要………………………………………………………………iii 研究背景……………………………………………………………… 1 材料與方法…………………………………………………………… 5 結果……………………………………………………………………10 討論……………………………………………………………………13 參考文獻………………………………………………………………17 附錄……………………………………………………………………33 表一.Nested Case-Control study：病例組與對照組進入研究之基本特徵…………………………………………………………22 表二.Nested Case-Control study：核苷酸與基因型的關係……………………23 表三.Nested Case-Control study：控制基因型後仍與HCC顯著的SNP其生物特徵…………………………………………………24 表四.Nested Case-Control study：核苷酸變異的累積與HBeAg、anti-Hbe和HCC的關係……………………………………………25 表五.Longitudinal cohort study：病例組與對照組之基本特徵………26 表六.Longitudinal cohort study：SNP長期變異之穩定性…………….27 表七.Longitudinal cohort study：SNP與HCC進程之關係…………….28 表八.Longitudinal cohort study：長期HBV DNA濃度之Trajectory groups其生物特徵…………………………………………………29 圖一.研究設計之流程圖..........................................................................31 圖二.Longitudinal Ccohort study：長期HBV DNA濃度之Trajectory分析………………………………………………………………32 | |
| dc.language.iso | zh-TW | |
| dc.title | B型肝炎病毒核基因上變異和肝細胞癌之關係：縱斷世代研究 | zh_TW |
| dc.title | Genetic Variation in the Core Gene of Hepatitis B Virus and Hepatocellular Carcinoma: A Longitudinal Cohort Study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 葉昭廷(Chau-Ting Yeh),劉信孚(Hsin-Fu Liu),劉俊人(Chun-Jen Liu) | |
| dc.subject.keyword | B型肝炎病毒,核基因,單點核苷,酸變異,HBV DNA濃度,肝細胞癌, | zh_TW |
| dc.subject.keyword | Hepatitis B virus,core gene,single nucleotide polymorphisms,HBV DNA levels,Hepatocellular carcinoma, | en |
| dc.relation.page | 32 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2008-07-25 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf | 325 kB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。